Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.06 is 35% above its 3-year average of 0.04, near the high end of its 3-year range (-0.29–0.07).
As of the fiscal period ended Tuesday, June 30, 2026. 5.44% below its 12-month average of 0.06.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.06.
DEBT TO EQUITY RATIO
0.06
DEBT TO EQUITY RATIO AVG TTM
0.06
DEBT TO EQUITY RATIO AVG 3Y
0.04
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-5.44%
CURRENT VS 3Y AVG
+35.12%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 773 covered companies
CURRENT VS SECTOR MEDIAN
-47.00%
vs the sector median at left
Market Cap
$1.61B
Debt to Equity Ratio
0.15
TTM Avg
0.18
3Y Avg
0.78
5Y Avg
0.76
Market Cap
$1.62B
Debt to Equity Ratio
N/A
TTM Avg
40.93
3Y Avg
29.06
5Y Avg
18.39
Market Cap
$1.63B
Debt to Equity Ratio
0.55
TTM Avg
1.03
3Y Avg
0.88
5Y Avg
0.88
Market Cap
$1.59B
Debt to Equity Ratio
0.34
TTM Avg
0.20
3Y Avg
0.20
5Y Avg
4.45
Market Cap
$1.57B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$1.54B
Debt to Equity Ratio
39.03
TTM Avg
3.28
3Y Avg
1.64
5Y Avg
1.11
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Septerna Inc (SEPN) | $1.61B | 0.06 | 0.06 | 0.04 | N/A |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | 0.15 | 0.18 | 0.78 | 0.76 |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 0.15 | 0.24 | 0.39 | 0.43 |
| uniQure N.V. (QURE)vs › | $1.60B | 0.19 | 2.70 | 1.22 | 0.84 |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | N/A | 40.93 | 29.06 | 18.39 |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 0.55 | 1.03 | 0.88 | 0.88 |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | 0.34 | 0.20 | 0.20 | 4.45 |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | 0.01 | 0.01 | 0.01 | 0.01 |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | 39.03 | 3.28 | 1.64 | 1.11 |
| Innoviva, Inc. (INVA)vs › | $1.54B | 0.22 | 0.44 | 0.63 | 0.69 |
Debt/Equity
0.06
Current Ratio
4.99
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.06 |
| 2026-03-31 | 0.06 |
| 2025-12-31 | 0.06 |
| 2025-09-30 | 0.06 |
| 2025-06-30 | 0.07 |
| 2025-03-31 | 0.06 |
| 2024-12-31 | 0.06 |
| 2024-09-30 | -0.29 |
| 2024-06-30 | -0.18 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
